Prostate-specific Membrane Antigen
Showing 1 - 25 of >10,000
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy
Recruiting
- PSMA-positive Metastatic Castration-resistant Prostate Cancer Treated With PSMA Radionuclide Therapy
- PSMA radionuclide therapy
-
Dallas, TexasMethodist Dallas Medical Center
Aug 9, 2023
Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide
Not yet recruiting
- Prostate Adenocarcinoma
- +2 more
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
- Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 4, 2023
Prostate Cancer Trial in Tomsk (Whole body study and SPECT with [99mTc]Tc-BQ0413)
Enrolling by invitation
- Prostate Cancer
- Whole body study and SPECT with [99mTc]Tc-BQ0413
-
Tomsk, Russian FederationTomskNRMC
Oct 26, 2023
Prostate Specific Membrane Antigen PET/CT in Biopsy Free of PSA
Recruiting
- Prostatic Neoplasms
- Radical prostatectomy (RP)
-
Xi'an, Shaanxi, ChinaFirst Affiliated Hospital of Xi'an Jiaotong University
Jul 14, 2023
Castration-Resistant Prostatic Cancer Trial ([Lu-177]-PNT2002)
Available
- Castration-Resistant Prostatic Cancer
- (no location specified)
Sep 11, 2023
Prostate Cancer Trial in United States (PSMA-PET CT)
Not yet recruiting
- Prostate Cancer
- PSMA-PET CT
-
Los Angeles, California
- +3 more
Jul 6, 2023
Prostate Cancer Trial in Leuven (68Ga-PSMA (HBED-CC) PET)
Recruiting
- Prostate Cancer
- 68Ga-PSMA (HBED-CC) PET
-
Leuven, BelgiumUZLeuven
Nov 18, 2022
Malignancy Trial in Beijing (Al18F-PSMA-BCH PET/CT)
Recruiting
- Malignancy
- Al18F-PSMA-BCH PET/CT
-
Beijing, Chaoyang, ChinaNational Cancer Center/Cancer Hospital,Chinese Academy of Medica
Mar 7, 2023
Prostate Cancer Trial (Darolutamide Oral Tablet [Nubeqa])
Not yet recruiting
- Prostate Cancer
- Darolutamide Oral Tablet [Nubeqa]
- (no location specified)
Jun 2, 2023
Prostate Cancer Trial in New York (engineered autologous T cells, cyclophosphamide)
Active, not recruiting
- Prostate Cancer
- engineered autologous T cells
- cyclophosphamide
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Nov 28, 2022
Prostate Cancer, Prostate Adenocarcinoma, Prostatic Tumors Trial in Montreal (131I-PSMA-1095 Radioligand Therapy (RLT))
Active, not recruiting
- Prostate Cancer
- +5 more
- 131I-PSMA-1095 Radioligand Therapy (RLT)
-
Montreal, Quebec, CanadaStephan Probst
Oct 24, 2022
Prostatic Tumors, Castration-Resistant Trial in Rotterdam (Radionuclide Therapy)
Recruiting
- Prostatic Neoplasms, Castration-Resistant
- Radionuclide Therapy
-
Rotterdam, Zuid-Holland, NetherlandsErasmus Medical Center
Jun 5, 2023
Cancer, Prostate Cancer, Metastatic Cancer Trial (177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended
Not yet recruiting
- Cancer
- +3 more
- 177Lu-PSMA-I&T - escalating renal absorbed dose
- 177Lu-PSMA-I&T - recommended phase 2 regime
- (no location specified)
Jun 14, 2023
Prostate Cancer Diagnosis Trial in Los Angeles (diagnostic test, other, drug)
Not yet recruiting
- Prostate Cancer Diagnosis
- PSMA PET scan
- +2 more
-
Los Angeles, CaliforniaVA Greater Los Angeles Healthcare System
Apr 20, 2023
PET/CT Characterization of Treatment Resistance
Recruiting
- Prostate Cancer
- F-fluorodeoxyglucose positron emission tomography (FDG PET)
- prostate-specific membrane antigen positron emission tomography (PSMA PET)
-
Madison, WisconsinUniversity of Wisconsin
Jan 24, 2023
Oligometastatic Prostate Cancer (OMPC) Trial (AAA617)
Not yet recruiting
- Oligometastatic Prostate Cancer (OMPC)
- (no location specified)
Jul 3, 2023
Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent Trial in Dallas (68Ga-PSMA-11, Positron Emission
Available
- Prostate Cancer
- +2 more
- 68Ga-PSMA-11
- Positron Emission Tomography/Computed Tomography
-
Dallas, TexasUT Southwestern Medical Center
Sep 27, 2022
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Tumor in the Bone, Stage IVB Prostate Cancer AJCC v8 Trial in San
Not yet recruiting
- Castration-Resistant Prostate Carcinoma
- +2 more
- Radium-223
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jun 20, 2023
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer Trial in
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- +2 more
- 177Lu HTK03170
- 68Ga-HTK03149
-
Vancouver, British Columbia, CanadaBC Cancer
Nov 28, 2022
Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer Trial in Madison (18F-DCFPyL)
Recruiting
- Breast Cancer
- +2 more
-
Madison, WisconsinUniversity of Wisconsin School of Medicine and Public Health
Oct 18, 2022
Prostate Cancer, Recurrent Prostate Cancer Trial in Tampa (F-DCFPyL Injection, PSMA PET)
Recruiting
- Prostate Cancer
- Recurrent Prostate Cancer
- F-DCFPyL Injection
- PSMA PET
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 24, 2023
18F Prostate-specific Membrane Antigen PET/CT in Prostate Cancer
Recruiting
- Prostatic Neoplasms
- Positron emission tomography/computerized tomography (PET/CT)
-
Xi'an, Shaanxi, ChinaFirst Affiliate Hospital of Xi'an Jiaotong University
Mar 23, 2022
Prostate Cancer Trial in St Leonards, Perth (177Lu-DOTA-TLX591)
Not yet recruiting
- Prostate Cancer
- 177Lu-DOTA-TLX591
-
St Leonards, New South Wales, Australia
- +1 more
Jul 18, 2022
Prostate Cancer Trial in New York (huJ591)
Active, not recruiting
- Prostate Cancer
-
New York, New YorkWeill Cornell Medical College
Apr 20, 2022
Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma Trial in Nijmegen (Lutetium-177-PSMA-I&T)
Recruiting
- Salivary Gland Cancer
- +2 more
-
Nijmegen, Gelderland, NetherlandsRadboudumc
Oct 27, 2022